Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.
INCLUDED IN THIS TRENDLINE
– Novo obesity drug protects heart health in large trial
– New kind of obesity drug sets ‘high bar’ in mid-stage study
– Lilly’s fortunes rise on back-to-back success for obesity, Alzheimer’s drugs
Join our community of smart and fun people from across the world who generously share their ideas, learnings, and resources with each other. We’ll also, send a short summary directly to your inbox never more than once a week.
© 2024 Marketboats Consulting, Inc. All Rights Reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.